Neither format offers a different route, so route is not what is being compared here. The declared unit is. Endoca’s raw capsules declare CBD+CBDa per capsule at 10 mg, 50 mg and 200 mg, with the medium size holding 300 mg across a 30-capsule bottle. The gummies declare on a different basis. Chill and Restore state 1,200 mg of full spectrum hemp oil for the whole jar, and Mountain High states 300 mg of full spectrum hemp extract for a single piece, which is extract weight and not cannabinoid weight. Nobody has run a study setting one format against the other in people, at any dose or over any duration.
The capsule fill does not remove the food effect. In 8 adults with refractory epilepsy, 99 percent pure cannabidiol in capsules taken with a high-fat meal of 840 to 860 calories produced a peak concentration 14-fold higher and total exposure 4-fold higher than the same capsules fasted. The pharmacokinetic work behind Epidyolex points the same way at 750 and 1,500 mg: a 5-fold rise on peak concentration and a 4-fold rise on exposure.
Mostly it shows up in whether the number printed on the unit can be trusted. LC-MS/MS analysis of 56 CBD gummy products from national brands found a mean of 21.38 mg of cannabidiol per gummy across a range of 5.70 to 59.99 mg, with 70 percent of products more than 10 percent away from the labelled dose and measurable variation between gummies from one bottle. In the same set, 39 percent contained delta-9-THC at 0.019 to 0.88 mg per piece. A capsule figure is not automatically better, but it is the format where a per-unit number is routinely published against a batch certificate.
Two practical differences follow. A gummy brings a sugar and gelling matrix and a flavouring with it, and a capsule brings none of that, which matters for a daily routine held for months. And Endoca’s raw capsules are unheated, so the label reads CBD+CBDa, while the gummies are sold on cannabidiol or hemp extract weight. If swallowing capsules is the obstacle, that is a sound reason to choose a gummy, and a better one than an absorption claim nobody has measured.
Two fixed-dose formats: one has been measured in people twice, the other not once. The gummy literature is analytical rather than pharmacokinetic, and it carries the useful lesson here: check the batch certificate for the unit you are swallowing rather than reasoning from the format it arrives in.
Choose capsules if you want the same amount daily with no sugar and no flavouring, and a declared CBD+CBDa figure per unit that is easy to set against the FSA 10 mg a day advice. Choose gummies if swallowing a capsule is the problem, or if a capsule is the thing you forget and a sweet is the thing you remember. Neither has a measured absorption advantage, so the decision rests on the label, the batch certificate and whether you want trace THC in the product at all. Neither is a sensible starting point at 200 mg.
Capsules and gummies are both CBD food supplements, and CBD food products are novel foods under Regulation (EU) 2015/2283 as retained in UK law, so each product requires authorisation before being placed on the market. The FSA public list is product-specific: a jar and a bottle are separate entries, and appearing on the list is not an authorisation nor a guarantee of one. Claims are narrower than people expect. Regulation (EC) 1924/2006 bars an unauthorised health claim, and no cannabidiol claim is authorised, so even a statement that one format absorbs better would be a claim with no evidence behind it.
FSA advice from October 2023 is that healthy adults should consume no more than 10 mg of CBD a day, which puts a single 10 mg capsule at the whole of that figure and a 50 mg capsule at five times it. The FSA advises against CBD for anyone under 18, anyone taking medication, anyone trying to conceive and anyone pregnant or breastfeeding. The exempt product definition in the Misuse of Drugs Regulations 2001 caps controlled cannabinoids at 1 mg per container, and Government Chemist guidance confirms that applies to the whole jar or bottle rather than one piece.
Capsules and gummies draw on extract from the same hemp, grown on our own land and processed with our own supercritical CO2 equipment, with batch analysis published since 2010. Every batch goes to third party laboratories, where HPLC and NMR fix the cannabinoid figures and a screen covers more than 200 pesticides alongside heavy metals and mycotoxins, with the reports kept at lab.endoca.com. Those documents settle what one capsule holds and what a jar totals. They cannot settle what reaches the blood, since no accepted method does that for cannabidiol.
Strength is a property of the unit rather than of the format. The capsules come at 10 mg, 50 mg and 200 mg of CBD+CBDa each, and the gummy jars are labelled 1,200 mg for the jar or hemp extract weight for one piece. Absorption has never been compared, so strength here means declared strength.
Some products do. In 56 CBD gummy products tested by LC-MS/MS, 39 percent contained delta-9-THC at 0.019 to 0.88 mg per gummy. UK law caps controlled cannabinoids at 1 mg per container. Endoca’s Restore and Energy gummies are broad spectrum and sold as THC free.
In principle they are level, since both arrive as fixed units. In practice the published analytical work favours the format carrying a per-unit cannabinoid figure on a batch certificate. In the 56-product gummy set, 70 percent of products sat more than 10 percent from the labelled dose.
A single 10 mg capsule equals the whole figure, and a 50 mg capsule is five times it. For gummies the comparison needs the batch certificate, because Mountain High declares hemp extract weight per piece and the Chill and Restore jars declare 1,200 mg per jar rather than per sweet.
Johnson DA, Funnell MP, Heaney LM, Cable TG, Wheeler PC, Bailey SJ, Clifford T, James LJ. Cannabidiol Oil Ingested as Sublingual Drops or Within Gelatin Capsules Shows Similar Pharmacokinetic Profiles in Healthy Males. Cannabis Cannabinoid Res 2024;9:e1423-e1432.
Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski M, Gramling-Aden M, Leppik IE. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia 2019;60:1586-1592.
Johnson ED, Kilgore MW, Stafford M, Randolph M, Glover M, Babalonis S. Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. Cannabis Cannabinoid Res 2025;10:710-718.
Millar SA, Stone NL, Yates AS, O’Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol 2018;9:1365.
Epidyolex 100 mg/ml oral solution. Summary of product characteristics, section 5.2, 2025.
Food Standards Agency. Cannabidiol (CBD): consumer advice and the public list of CBD food products. Updated 2026.
Government Chemist. Guidance on Analytical Limits for Controlled Cannabinoids in Specified Products Containing Cannabidiol (CBD). January 2021.
Last reviewed 1 October 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.